Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy

Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story Multiple drivers to deliver mid-single digit top-line growth¹ in the mid-term Expanding breadth and depth of pipeline Additional M&A activity E D C B Leveraging A Sales Maximizing near-term Improving product mix strategic partnerships execution Biosimilars launches Mid-single digit net sales growth¹ in the mid-term (2028) Included in business plan 1. In constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31 12 Management Presentation Incremental growth Upside to business plan SANDOZ

View entire presentation